171 related articles for article (PubMed ID: 35990747)
1. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa.
Lenders M; Pollmann S; Terlinden M; Brand E
Mol Ther Methods Clin Dev; 2022 Sep; 26():323-330. PubMed ID: 35990747
[TBL] [Abstract][Full Text] [Related]
2. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease.
Lenders M; Feidicker LM; Brand SM; Brand E
Front Immunol; 2023; 14():1266082. PubMed ID: 37818380
[TBL] [Abstract][Full Text] [Related]
3. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Linhart A; Dostálová G; Nicholls K; West ML; Tøndel C; Jovanovic A; Giraldo P; Vujkovac B; Geberhiwot T; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Hughes D
Orphanet J Rare Dis; 2023 Oct; 18(1):332. PubMed ID: 37865771
[TBL] [Abstract][Full Text] [Related]
5. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.
Lenders M; Brand E
Front Immunol; 2022; 13():1024963. PubMed ID: 36569886
[TBL] [Abstract][Full Text] [Related]
6. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity.
Stappers F; Scharnetzki D; Schmitz B; Manikowski D; Brand SM; Grobe K; Lenders M; Brand E
J Inherit Metab Dis; 2020 Mar; 43(2):334-347. PubMed ID: 31587315
[
